Our data indicated that the anti-proliferative and chemosensitization effect of pristimerin on pancreatic cancer cells may be mediated through the inhibition of NF-κB activity and alteration of cell cycle- and apoptosis-related proteins. Here, NFKB1 is linked to pancreatic neoplasm.